ESR1 and breast cancer: Although traditional biomarkers like estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) have guided clinical decisions (Figure 5), recent advancements in molecular profiling have brought to light promising novel biomarkers for breast cancer diagnoses, prognoses, and treatment response predictions.